Beranda › Kanker Paru › Massachusetts › Springfield
Uji klinis Kanker Paru di Springfield, MA
5 studi untuk Kanker Paru mencari peserta di lokasi sekitar Springfield (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Menerima pesertaFase 3
- Baystate Medical Center, Springfield
A Community Health Intervention to Improve Lung Cancer Screening Uptake in Community Health Centers
Menerima pesertaSukarelawan sehat diterima
- Baystate Health, Springfield
Integrated Cancer Repository for Cancer Research
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Holyoke Medical Center, Holyoke · 7 mi jauhnya
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Baystate Medical Center, Springfield
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2/3
- Baystate Medical Center, Springfield
Uji klinis Kanker Paru di kota lain
- Houston, TX78 studi
- Boston, MA62 studi
- New York City, NY60 studi
- Los Angeles, CA45 studi
- Washington, DC41 studi
- Arlington, VA41 studi
- Chicago, IL41 studi
- Nashville, TN40 studi
- Baltimore, MD40 studi
- St. Louis, MO39 studi
- Columbus, OH37 studi
- Philadelphia, PA36 studi
Studi lain di Springfield
- Kanker Ovarium5 studi
- Degenerasi Makula4 studi
- Kanker Paru Non-Sel Kecil4 studi
- Overdosis Opioid3 studi
- Melanoma3 studi
- Kanker Endometrium3 studi
- Penyakit Arteri Koroner3 studi
- Gangguan Depresi Mayor3 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.